Tadayoshi Kogure
Overview
Explore the profile of Tadayoshi Kogure including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qiang N, Ao J, Nakamura M, Katayama K, Zhang J, Kogure T, et al.
Biochem Pharmacol
. 2025 Feb;
235:116829.
PMID: 40015652
Lenvatinib (LEN)-treated patients with hepatocellular carcinoma (HCC) are frequently accompanied by skeletal muscle loss, which is correlated with poor prognosis. Interactions between tumor and skeletal muscle may play a role...
2.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, et al.
Drugs Real World Outcomes
. 2023 Jul;
10(4):513-520.
PMID: 37466822
Background: Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far,...
3.
Kojima R, Nakamoto S, Kogure T, Ma Y, Ogawa K, Iwanaga T, et al.
World J Virol
. 2023 Jul;
12(3):209-220.
PMID: 37396703
Background: Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). HBV DNA can get integrated into the hepatocyte genome to promote carcinogenesis. However, the precise mechanism by...
4.
Yumita S, Ogasawara S, Nakagawa M, Maruta S, Okubo T, Itokawa N, et al.
BMC Gastroenterol
. 2023 Apr;
23(1):101.
PMID: 37003980
Background: Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of...
5.
Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, et al.
Int Immunopharmacol
. 2023 Mar;
118:110068.
PMID: 37001386
Enhancer of zeste homolog 2 (EZH2), a core component of polycomb repressive component 2 is overexpressed in a variety of cancers and recognized as a therapeutic target molecule. However, EZH2...
6.
Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, Qiang N, et al.
Biochem Biophys Res Commun
. 2022 Dec;
642:192-200.
PMID: 36586187
Transforming growth factor (TGF)-β/Smad pathway is implicated in the pathogenesis of liver fibrosis, a condition characterized by excessive deposition of extracellular matrix (ECM) proteins such as collagen in response to...
7.
Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, et al.
Cancer
. 2022 Nov;
129(4):590-599.
PMID: 36426410
Background: Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long-term efficacy and association with adverse events in real-world practice are unknown. This study was designed...
8.
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36233317
A functional cure of hepatitis B virus (HBV) infection or HB antigen loss is rarely achieved by nucleos(t)ide analogs which target viral polymerase. HBx protein is a regulatory protein associated...